6th Jul 2011 13:24
6 July 2011
Plethora Solutions Holdings plc
("Plethora" or "the Company")
Result of AGM
Plethora Solutions Holdings plc (AIM: PLE), the UK-based speciality pharmaceutical company, announces that at the Company's annual general meeting held today all resolutions were passed.
-Ends-
Enquiries:
Plethora Solutions Ronald Openshaw | Tel : +44(0) 20 3077 5400 |
Daniel Stewart (Nomad & Joint Broker) Paul Shackleton (Nomad) Martin Lampshire (Broker) | Tel : +44(0) 20 7776 6550
|
Hybridan LLP (Joint Broker) Claire Louise Noyce | Tel: +44(0) 20 7947 4350
|
Hansard Communications Nicholas Nelson/Guy McDougall | Tel: +44(0) 20 7245 1100
|
Notes to Editors:
Further information on products available through The Urology Company can be found at www.theurologyco.com
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503 - Virgafem), interstitial cystitis (PSD597 - Urolieve) erectile dysfunction (PSD510) and premature ejaculation (PSD502).
Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of branded and generic pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, andrology and obstetric conditions.
The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk and www.theurologyco.com
Related Shares:
Plethora Solutions Holdings Plc